Seven Eight Capital, LP Exelixis, Inc. Transaction History

Seven Eight Capital, LP

$1.05 Billion
Q3 2024

A detailed history of Seven Eight Capital, LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Seven Eight Capital, LP holds 84,392 shares of EXEL stock, worth $2.92 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares

84,392

Previous 96,404 12.46%

Holding current value

$2.92 Million

Previous $2.17 Million 1.06%

% of portfolio

0.21%

Previous 0.24%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$21.96 - $27.6 $263,783 - $331,531	-12,012 Reduced 12.46%	84,392 $2.19 Million
Q2 2024 Aug 12, 2024	BUY	$20.34 - $23.73 $421,912 - $492,231	20,743 Added 27.42%	96,404 $2.17 Million
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $1.07 Million - $1.27 Million	53,024 Added 234.24%	75,661 $1.8 Million
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $16,786 - $21,041	872 Added 4.01%	22,637 $543,000
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $158,127 - $188,855	8,305 Added 61.7%	21,765 $475,000
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $244,568 - $275,660	13,460 New	13,460 $257,000
Q3 2022 Nov 10, 2022	BUY	$15.68 - $22.27 $449,435 - $638,325	28,663 Added 244.29%	40,396 $633,000
Q2 2022 Aug 04, 2022	SELL	$17.44 - $23.16 $150,594 - $199,986	-8,635 Reduced 42.39%	11,733 $244,000
Q1 2022 May 11, 2022	BUY	$17.03 - $22.67 $346,867 - $461,742	20,368 New	20,368 $462,000
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $1.48 Million - $2.1 Million	-82,300 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$18.39 - $24.8 $1.51 Million - $2.04 Million	82,300 New	82,300 $1.65 Million
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $374,127 - $487,614	-18,100 Closed	0 $0
Q2 2020 Aug 06, 2020	BUY	$16.46 - $27.42 $21,398 - $35,646	1,300 Added 7.74%	18,100 $430,000
Q1 2020 May 14, 2020	SELL	$14.46 - $21.8 $1.13 Million - $1.71 Million	-78,411 Reduced 82.35%	16,800 $289,000
Q4 2019 Feb 13, 2020	SELL	$15.15 - $18.89 $972,630 - $1.21 Million	-64,200 Reduced 40.27%	95,211 $1.68 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $153,727 - $196,941	8,695 Added 5.77%	159,411 $2.82 Million
Q2 2019 Aug 12, 2019	SELL	$18.93 - $24.75 $1.17 Million - $1.53 Million	-61,800 Reduced 29.08%	150,716 $3.22 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $3.85 Million - $4.86 Million	196,300 Added 1210.53%	212,516 $5.06 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $414,960 - $662,720	-30,400 Reduced 65.21%	16,216 $319,000
Q3 2018 Oct 18, 2018	SELL	$15.87 - $22.4 $1.32 Million - $1.87 Million	-83,400 Reduced 64.15%	46,616 $826,000
Q2 2018 Aug 07, 2018	BUY	$18.56 - $22.45 $2.1 Million - $2.54 Million	113,100 Added 668.6%	130,016 $2.8 Million
Q1 2018 May 14, 2018	SELL	$22.15 - $31.89 $3.36 Million - $4.83 Million	-151,494 Reduced 89.96%	16,916 $375,000
Q4 2017 Feb 12, 2018	BUY	$24.23 - $30.93 $4.08 Million - $5.21 Million	168,410 New	168,410 $5.12 Million
Q3 2017 Oct 16, 2017	SELL	$23.35 - $29.24 $1.14 Million - $1.43 Million	-48,987 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	48,987	48,987 $1.21 Million

Others Institutions Holding EXEL

# of Institutions

500

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.2B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Account

Seven Eight Capital, LP Exelixis, Inc. Transaction History